Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Apr 28, 2015
Insider Transaction Report
Form 4
Schiller Howard Bradley
DirectorChairman and CEO
Transactions
- Exercise/Conversion
Common Stock, no par value
[F2][F1]2015-04-27+22,500→ 306,007 total - Tax Payment
Common Stock, no par value
[F3]2015-04-27−11,779→ 294,228 total - Tax Payment
Common Stock, no par value
[F4]2015-04-27−4,859→ 289,369 total - Exercise/Conversion
Restricted Share Units
[F1][F2]2015-04-27−22,500→ 0 total→ Common Stock (22,500 underlying)
Footnotes (4)
- [F1]Each performance-based Restricted Share Unit ("PSU") represents a contingent right to receive between zero and three common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
- [F2]These RSUs were initially eligible to vest based on total shareholder return ("TSR") between a price of $42.70 starting on December 1, 2011 and the average stock price for the 20 trading days starting on each measurement dates: 25% on September 1, 2014, 50% on December 1, 2014 and 25% on March 1, 2015, contingent on TSR performance between 15% and 45% into between one and three Common Shares of common stock, respectively, with early vesting possible at higher TSR levels. These PSUs have now vested in full.
- [F3]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs.
- [F4]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Matching Restricted Share Units.
Signature
by: Nicholas Zanoni for Howard Schiller|2015-04-28